

p70 S6 Kinase Phospho (pT421/pS424)

Rabbit Monoclonal Antibody | Product Data Sheet

Catalog# 1135-1

Quantity: 100ul

Clone ID: E135

Species Cross-reactivity* + Human - Mouse - Rat

Applications: + WB - IHC - ICC + IP - FC

Lot #: Please refer to vial

Molecular Wt.: 70 kDa

UniProt ID: P23443

Background: p70 S6 Kinase is a mitogen-activated Ser/Thr protein kinase that is required for cell growth and G1 cell cycle progression (1). p70 S6 kinase phosphorylates specifically ribosomal protein S6. Activation of p70 S6 kinase is controlled by multiple phosphorylation events located within the catalytic, linker and pseudosubstrate domains (2). Activation occurs via phosphorylation at Ser411, Thr421 and Ser424 within the pseudosubstrate region (3, 4).

Specificity: A synthetic phospho-peptide corresponding to residues surrounding Thr421 and Ser424 of human p70 S6 Kinase alpha was used as immunogen. The antibody only detects p70-S6K phosphorylated on Threonine 421 and Serine 424.

Storage Condition and Buffer: Store at -20 °C. Buffer: Antibody buffer, sodium azide, glycerol, and BSA. Stable for 12 months from date of receipt.

Recommended Dilutions:

WB: 1:2,500

IP: 1:20

Background References:

1. Pearson, R.B. and G. Thomas. Regulation of p70s6k/p85s6k and its role in the cell cycle. *Prog Cell Cycle Res.* 1: 21
2. Pullen, N. and G. Thomas. The modular phosphorylation and activation of p70s6k. *FEBS Lett.* 410: 78
3. Dufner, A. and G. Thomas. Ribosomal S6 kinase signaling and the control of translation. *Exp Cell Res.* 253: 100
4. Le, X.F., et al. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. *Oncogene* 22: 484

*Cross reactivity determined by western blot only.

Product QC'd by:




Fig 1. A. Western blot analysis on 293T cell lysate using anti-Phospho-p70 S6 Kinase (pT421/pS424) RabMAb (cat. #1135-1); dilution 1:2,500. Cell lysates were either (1) untreated or (2) treated with EGF.

For research use only. Not for use in diagnostic or therapeutic applications.

This product was manufactured under U.S. Patent No. 5,675,063. For a complete list of protocols and available related products, please visit www.epitomics.com
Epitomics, Inc., 863 Mitten Road, Suite 103 Burlingame, California 94010-1303